Cargando…
Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cult...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519593/ https://www.ncbi.nlm.nih.gov/pubmed/22625224 http://dx.doi.org/10.1186/1471-2334-12-123 |
_version_ | 1782252695035314176 |
---|---|
author | Sathler-Avelar, Renato Vitelli-Avelar, Danielle Marquete Elói-Santos, Silvana Maria Gontijo, Eliane Dias Teixeira-Carvalho, Andréa Martins-Filho, Olindo Assis |
author_facet | Sathler-Avelar, Renato Vitelli-Avelar, Danielle Marquete Elói-Santos, Silvana Maria Gontijo, Eliane Dias Teixeira-Carvalho, Andréa Martins-Filho, Olindo Assis |
author_sort | Sathler-Avelar, Renato |
collection | PubMed |
description | BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cultures to describe the cytokine profile of Bz-treated Indeterminate Chagas disease patients-(INDt) as compared to untreated patients-(IND). RESULTS: Our findings showed that IND presented increased levels of IL-10(+)neutrophils, IL-12(+) and IL-10(+)monocytes and IFN-γ(+)NK-cells. Moreover, IND showed slight increase of IL-4(+)CD4(+)T-cells and enhanced levels of IL-10(+)CD8(+)T-cells and B-cells. Additional analysis of cytokine Low and High producers also highlighted the presence of High cytokine producers within IND, including IL-10 from CD4+ T-cells and IFN-γ from CD8(+) T-cells, as compared to NI. The Bz-treatment lead to an overall cytokine down-regulation in the innate and adaptive compartments, including low levels of IL-12(+) and IL-10(+)neutrophils and monocytes, IFN-γ(+)NK-cells, IL-12(+), TNF-α(+), IFN-γ(+) and IL-5(+)CD4(+)T-cells and IL-10(+)B-cells, along with basal levels of cytokine-expressing CD8(+)T-cells in INDt as compared to IND. The in vitro antigen stimulation shifted the cytokine profile toward a type 1-modulated profile, with increased levels of IL-12(+) and IL-10(+) monocytes, IFN-γ(+) and IL-4(+)NK-cells along with TNF-α(+) and IFN-γ(+)CD8(+)T-cells. Analysis of Low and High cytokine producers, upon in vitro antigen stimulation, further confirm these data. CONCLUSION: Together, our findings showed that the Bz treatment of Indeterminate Chagas’ disease patients shifts the cytokine patterns of peripheral blood monocytes, NK-cells and CD8(+) T-cells towards a long-lasting Type-1-modulated profile that could be important to the maintenance of a non-deleterious immunological microenvironment. |
format | Online Article Text |
id | pubmed-3519593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35195932012-12-12 Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens Sathler-Avelar, Renato Vitelli-Avelar, Danielle Marquete Elói-Santos, Silvana Maria Gontijo, Eliane Dias Teixeira-Carvalho, Andréa Martins-Filho, Olindo Assis BMC Infect Dis Research Article BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cultures to describe the cytokine profile of Bz-treated Indeterminate Chagas disease patients-(INDt) as compared to untreated patients-(IND). RESULTS: Our findings showed that IND presented increased levels of IL-10(+)neutrophils, IL-12(+) and IL-10(+)monocytes and IFN-γ(+)NK-cells. Moreover, IND showed slight increase of IL-4(+)CD4(+)T-cells and enhanced levels of IL-10(+)CD8(+)T-cells and B-cells. Additional analysis of cytokine Low and High producers also highlighted the presence of High cytokine producers within IND, including IL-10 from CD4+ T-cells and IFN-γ from CD8(+) T-cells, as compared to NI. The Bz-treatment lead to an overall cytokine down-regulation in the innate and adaptive compartments, including low levels of IL-12(+) and IL-10(+)neutrophils and monocytes, IFN-γ(+)NK-cells, IL-12(+), TNF-α(+), IFN-γ(+) and IL-5(+)CD4(+)T-cells and IL-10(+)B-cells, along with basal levels of cytokine-expressing CD8(+)T-cells in INDt as compared to IND. The in vitro antigen stimulation shifted the cytokine profile toward a type 1-modulated profile, with increased levels of IL-12(+) and IL-10(+) monocytes, IFN-γ(+) and IL-4(+)NK-cells along with TNF-α(+) and IFN-γ(+)CD8(+)T-cells. Analysis of Low and High cytokine producers, upon in vitro antigen stimulation, further confirm these data. CONCLUSION: Together, our findings showed that the Bz treatment of Indeterminate Chagas’ disease patients shifts the cytokine patterns of peripheral blood monocytes, NK-cells and CD8(+) T-cells towards a long-lasting Type-1-modulated profile that could be important to the maintenance of a non-deleterious immunological microenvironment. BioMed Central 2012-05-24 /pmc/articles/PMC3519593/ /pubmed/22625224 http://dx.doi.org/10.1186/1471-2334-12-123 Text en Copyright ©2012 Sathler-Avelar et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sathler-Avelar, Renato Vitelli-Avelar, Danielle Marquete Elói-Santos, Silvana Maria Gontijo, Eliane Dias Teixeira-Carvalho, Andréa Martins-Filho, Olindo Assis Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title | Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title_full | Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title_fullStr | Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title_full_unstemmed | Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title_short | Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
title_sort | blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519593/ https://www.ncbi.nlm.nih.gov/pubmed/22625224 http://dx.doi.org/10.1186/1471-2334-12-123 |
work_keys_str_mv | AT sathleravelarrenato bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens AT vitelliavelardaniellemarquete bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens AT eloisantossilvanamaria bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens AT gontijoelianedias bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens AT teixeiracarvalhoandrea bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens AT martinsfilhoolindoassis bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens |